Spots Global Cancer Trial Database for Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
Official Title: Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
Study ID: NCT00081315
Interventions
Study Description
Brief Summary: The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cedars Sanai, Los Angeles, California, United States
Radiation Oncology Center, Sacramento, California, United States
The Center for Cancer Care, Torrington, Connecticut, United States
Florida Wellcare Alliance, Inverness, Florida, United States
Florida Community Cancer Center, New Port Richey, Florida, United States
Ormand Memorial Cancer Center, Ormand Beach, Florida, United States
Sarasota Memorial Hospital, Sarasota, Florida, United States
University Community Hospital-Center for Cancer Care, Tampa, Florida, United States
University of Kentucky, Lexington, Kentucky, United States
St. Agnes Health Care, Baltimore, Maryland, United States
Center for Cancer & Blood Disorders, Bethesda, Maryland, United States
Chesapeake Oncology-Hematology Associates, Glen Burnie, Maryland, United States
St. John's Medical Research, Springfield, Missouri, United States
Cooper University Hospital, Camden, New Jersey, United States
Long Island Jewish Medical Center, New Hyde Park, New York, United States
Beth Israel Hospital, New York, New York, United States
Upstate NY Cancer R&E Foundation, Rochester, New York, United States
New Hanover Radiation, Wilmington, North Carolina, United States
Cancer Center of Upper Delaware Valley, Milford, Pennsylvania, United States
Montgomery Cancer Center, Norristown, Pennsylvania, United States
Charleston Cancer Center, Charleston, South Carolina, United States
The Center for Radiation Oncology, Danville, Virginia, United States
Providence Everett Medical Center, Everett, Washington, United States
Valley Medical Center, Renton, Washington, United States
Contact Details
Name: Luz Hammershaimb, M.D.
Affiliation: MedImmune LLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
